Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem Cell Therapeutics (SCT), a biotechnology company focused on the development and commercialisation of drug-based therapies to treat central nervous system diseases, has received US Patent 7,704,737 entitled, 'Oligodendrocyte Production from Multipotent Neural Stem Cells.'
Subscribe to our email newsletter
The claims covers the use of granulocyte macrophage colony stimulating factor (GM-CSF) for producing oligodendrocytes from multipotent neural stem cells in culture. This is the second patent to issue in this patent family.
Alan Moore, president and CEO of SCT, said: “The technology covered by this patent is of potential use as cell transplant therapy for treating demyelinating diseases resulting from oligodendrocyte loss or damage, such as multiple sclerosis and spinal cord injury. This patent expands and adds value to SCT’s overall intellectual property portfolio.”
SCT’s patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.